Carmichael Hill & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Carmichael Hill & Associates’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-696	Closed	-$7.78K	–	799
2023 Q3	$7.78K	Hold	696	–	–	﹤0.01%	595
2023 Q2	$14.9K	Hold	696	–	–	0.01%	505
2023 Q1	$28.1K	Hold	696	–	–	0.01%	408
2022 Q4	$32.4K	Hold	696	–	–	0.02%	405
2022 Q3	$36K	Hold	696	–	–	0.02%	388
2022 Q2	$33K	Hold	696	–	–	0.02%	395
2022 Q1	$50K	Hold	696	–	–	0.02%	357
2021 Q4	$52K	Hold	696	–	–	0.02%	358
2021 Q3	$40K	Hold	696	–	–	0.02%	396
2021 Q2	$31K	Hold	696	–	–	0.02%	450
2021 Q1	$34K	Hold	696	–	–	0.02%	406
2020 Q4	$29K	Hold	696	–	–	0.02%	410
2020 Q3	$32K	Hold	696	–	–	0.02%	358
2020 Q2	$35K	Hold	696	–	–	0.03%	328
2020 Q1	$36K	Hold	696	–	–	0.03%	301
2019 Q4	$43K	Buy	+696	New	+$43.1K	0.03%	299

Other funds holding ENTA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Carmichael Hill & Associates's ENTA Position: Q4 2023 in Review

Carmichael Hill & Associates sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 696 shares — an estimated $7.78K sold.

Carmichael Hill & Associates first reported a position in ENTA in Q4 2019 and held it in 16 quarters. The position peaked at $52K in Q4 2021. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

Carmichael Hill & Associates reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Carmichael Hill & Associates sold 696 Enanta Pharmaceuticals shares in Q4 2023, an estimated $7.78K.
Carmichael Hill & Associates first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 16 quarters.
Carmichael Hill & Associates's Enanta Pharmaceuticals position peaked at $52K in Q4 2021.
105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Carmichael Hill & Associates's 13F filing for Q4 2023, filed 23 Jan 2024.